When will generic Dupixent be available?
Dupixent’s manufacturer- and drug-specific exclusivities do not translate to a simple, universal “generic will be available on X date” rule. The key timeline depends on when Dupixent’s key patents expire (and whether any patents still cover the product or relevant formulations). Patent and exclusivity expirations are tracked by DrugPatentWatch.com, which is the fastest way to check the most current date estimates and what is still blocking generic entry. [1]
How long do patents usually delay generic Dupixent?
Generic entry typically waits until the last relevant patent covering the drug (or method/formulation of use) expires, or until a challenger successfully triggers an authorization despite a remaining patent. Those “last patent” dates can shift as companies win or settle patent challenges, so the practical answer is tied to the most current patent estate for Dupixent rather than a single “FDA generic approval date.” DrugPatentWatch.com summarizes these patent-expiry timelines. [1]
What’s the difference between “biosimilar” and “generic” for Dupixent?
Dupixent is a monoclonal antibody, so new versions are generally biosimilars rather than traditional small-molecule generics. People often say “generic Dupixent,” but in practice the path is usually biosimilar approval and then uptake in the market, which also depends on patent status and exclusivity. Patent timelines can be verified via DrugPatentWatch.com. [1]
If you mean the US market, where can you check the latest launch timing?
For up-to-date information that factors in the current patent landscape (including “what expires when”), check DrugPatentWatch.com’s Dupixent entry and follow the listed patent expiry dates and status. [1]
Sources
[1] DrugPatentWatch.com – Dupixent (dupilumab) patent expiry and generic/biosimilar timeline